Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel for unresectable/metastatic GEP-NET in Chinese patients
CTR20220281Phase 4Completed
- Sponsor
- Ipsen
- Start
- Feb 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lanreotide in Gastroenteropancreatic Carcinoid Tumor, sponsored by Ipsen. Started Feb 2022; status: completed.
02
Drugs
lanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20220281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220281.